Literature DB >> 7926304

Combined analysis of autoantibodies improves prediction of IDDM in islet cell antibody-positive relatives.

P J Bingley1, M R Christie, E Bonifacio, R Bonfanti, M Shattock, M T Fonte, G F Bottazzo, E A Gale.   

Abstract

Prediction of insulin-dependent diabetes mellitus (IDDM) is still largely based on islet cell antibodies (ICAs), but it may be improved by combined analysis with other humoral markers. We examined autoantibodies to insulin (IAAs), glutamic acid decarboxylase (GAD), and M(r) 37,000 and M(r) 40,000 fragments of islet antigens (37 and 40 kDa) together with ICA subtypes in 101 family members with ICAs > or = 10 Juvenile Diabetes Foundation units (JDF U) followed for up to 14 years, of whom 18 have developed IDDM. Life-table analysis showed a 43% risk of IDDM within 10 years for those with ICAs > or = 10 JDF U, rising to 53% for those with ICAs > or = 20 JDF U. The risk for ICAs > or = 10 JDF U was 62% in the family members in the youngest age quartile (< 13.2 years) and fell with increasing age to 4% in those > 40.7 years of age (P = 0.03). ICAs > or = 10 JDF U combined with IAAs gave a risk of 84% (P = 0.03 compared with IAA-), and ICAs > or = 10 JDF U combined with GAD antibodies gave a risk of 61% (P = 0.018). The risk for ICAs > or = 10 JDF U with antibodies to 37-kDa antigen was 76% (P < 0.0001). Risk increased with the number of autoantibodies, from 8% for ICAs alone to 88% with > or = 3 autoantibodies (14 cases detected) (P < 0.0001). The increased risk associated with multiple antibodies was observed independent of age.(ABSTRACT TRUNCATED AT 250 WORDS)

Entities:  

Mesh:

Substances:

Year:  1994        PMID: 7926304     DOI: 10.2337/diab.43.11.1304

Source DB:  PubMed          Journal:  Diabetes        ISSN: 0012-1797            Impact factor:   9.461


  69 in total

Review 1.  T-cell reactivity to beta-cell antigens in human insulin-dependent (type 1) diabetes mellitus. Implications for diagnosis and therapy.

Authors:  B O Roep
Journal:  Clin Rev Allergy Immunol       Date:  2000-12       Impact factor: 8.667

2.  T-cell response to proinsulin and insulin in type 1 and pretype 1 diabetes.

Authors:  D Dubois-LaForgue; J C Carel; P F Bougnères; J G Guillet; C Boitard
Journal:  J Clin Immunol       Date:  1999-03       Impact factor: 8.317

Review 3.  Prospects for the prevention and reversal of type 1 diabetes mellitus.

Authors:  Nikolai Petrovsky; Diego Silva; Desmond A Schatz
Journal:  Drugs       Date:  2002       Impact factor: 9.546

Review 4.  Environmental triggers and determinants of beta-cell autoimmunity and type 1 diabetes.

Authors:  Mikael Knip
Journal:  Rev Endocr Metab Disord       Date:  2003-09       Impact factor: 6.514

Review 5.  Current approaches to measuring human islet-antigen specific T cell function in type 1 diabetes.

Authors:  S I Mannering; F S Wong; I Durinovic-Belló; B Brooks-Worrell; T I Tree; C M Cilio; N C Schloot; R Mallone
Journal:  Clin Exp Immunol       Date:  2010-09-15       Impact factor: 4.330

Review 6.  The case for an autoimmune aetiology of type 1 diabetes.

Authors:  S I Mannering; V Pathiraja; T W H Kay
Journal:  Clin Exp Immunol       Date:  2015-10-21       Impact factor: 4.330

7.  Longitudinal epitope analysis of insulin-binding antibodies in type 1 diabetes.

Authors:  T R Hall; J W Thomas; C J Padoa; C Torn; M Landin-Olsson; E Ortqvist; C S Hampe
Journal:  Clin Exp Immunol       Date:  2006-10       Impact factor: 4.330

8.  Type 1 diabetes risk assessment: improvement by follow-up measurements in young islet autoantibody-positive relatives.

Authors:  P Achenbach; K Warncke; J Reiter; A J K Williams; A G Ziegler; P J Bingley; E Bonifacio
Journal:  Diabetologia       Date:  2006-09-26       Impact factor: 10.122

9.  Biomarkers for type 1 diabetes.

Authors:  Sharad Purohit; Jin-Xiong She
Journal:  Int J Clin Exp Med       Date:  2008-02-29

10.  Combined positivity for HLA DQ2/DQ8 and IA-2 antibodies defines population at high risk of developing type 1 diabetes.

Authors:  K Decochez; I Truyen; B van der Auwera; I Weets; E Vandemeulebroucke; I H de Leeuw; B Keymeulen; C Mathieu; R Rottiers; D G Pipeleers; F K Gorus
Journal:  Diabetologia       Date:  2005-03-09       Impact factor: 10.122

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.